ExaGrid Named a Finalist in SDC Awards 2019
30.10.2019 14:00:00 EET | Business Wire | Press release
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been named a finalist in the Storage, Digitalisation + Cloud (SDC) Awards 2019. The SDC Awards – the new name for Angel Business Communications' IT awards – is firmly focused on recognizing and rewarding success in the products and services that are the foundation for digital transformation. ExaGrid’s EX Series backup storage appliances with data deduplication is nominated for “Backup Storage Innovation of the Year.” Voting to determine the winner in each category is underway now and closes on 15th November 2019 at 17:30 BST. The results will be revealed at an evening gala in London on 27th November 2019.
ExaGrid has gained the nomination due the EX Series’ uniquely scalable architecture and its specialized deduplication process. ExaGrid is best known for its industry-leading approach to backup storage with unique Landing Zone technology, Adaptive Deduplication approach, and cost-effective scale-out architecture. Managing data growth can cause strain on backup storage and ExaGrid set out to develop the best backup target possible. Through its intelligent hyperconverged storage for backup with data deduplication, ExaGrid helps IT organizations solve three of the most pressing issues they face today: how to protect and manage growing data, how to recover data as quickly as possible, and how to do so at a lower cost.
In data backup, organizations retain weekly, monthly and yearly backups in order to account for regulatory audits, legal discovery and other business reasons. It is not uncommon for organizations to retain 20 to 50 copies of their backup data at different historic points in time. As a result, the total backup storage can be 20 to 50 times greater than the initial primary storage copy. The cost of storage for backup becomes prohibitive and difficult to manage. The value that ExaGrid provides stems from its adaptive approach to deduplication, which offers a 20:1 data deduplication ratio. The ExaGrid system can easily scale to accommodate data growth. ExaGrid’s computing software makes the system highly scalable. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour, which is the highest in the industry. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic reducing IT staff maintenance and time.
The traditional inline approach to backup storage only stores deduplicated data. Therefore, both backups and restores are slow as data is deduplicated and rehydrated. As data grows, no additional compute resources are added – so the backup window grows until backups must be abandoned as they are cutting into production hours. Only an expensive, disruptive, forklift upgrade can resolve the longer backup windows. Instead, ExaGrid writes data straight to a disk Landing Zone for the fastest backups, while deduplication happens in parallel. The most recent backup is kept in undeduplicated form in its Landing Zone for the fastest restores and instant VM recovery, since no rehydration is necessary. Long-term retention data is stored deduplicated in the repository, which is a separate section of the appliance.
“ExaGrid’s nomination demonstrates the importance of innovation in the backup storage space and the need for a continued focus on data storage efficiency and cost savings,” said Bill Andrews, CEO and President of ExaGrid. “ExaGrid’s unique scale-out storage architecture provides all compute, network and storage resources for a fixed-length backup window as data grows. This provides essential time savings for strained IT staff. Our approach also eliminates expensive forklift upgrades and planned product obsolescence, which reduces the total cost of ownership for organizations looking to save storage space in their backup environment.”
ExaGrid supports all backup typologies including private cloud, offsite data center, third-party data center, third-party cloud, public cloud, and can operate in a pure hybrid environment.
Lastly, ExaGrid supports a wide variety of backup applications, utilities, and database dumps, such as Veeam, Commvault, Veritas NetBackup, IBM Spectrum Protect, HYCU, Zerto, Acronis and many others. ExaGrid allows multiple approaches within the same environment. An organization can use one backup application for its physical servers, a different backup application or utility for its virtual environment, and also perform direct Microsoft SQL or Oracle RMAN database dumps – all to the same ExaGrid system. This approach allows customers to use the backup application and utilities of their choosing, use best-of-breed backup applications and utilities, and choose the right backup application and utility for each specific use case. If the customer chooses to change their backup application in the future, the ExaGrid system will still work, protecting the initial investment.
About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique Landing Zone, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191030005092/en/
Contact information
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x0248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
